- CDC
- Heart Failure
- Cardiovascular Clinical Consult
- Adult Immunization
- Hepatic Disease
- Rare Disorders
- Pediatric Immunization
- Implementing The Topcon Ocular Telehealth Platform
- Weight Management
- Monkeypox
- Guidelines
- Men's Health
- Psychiatry
- Allergy
- Nutrition
- Women's Health
- Cardiology
- Substance Use
- Pediatrics
- Kidney Disease
- Genetics
- Complimentary & Alternative Medicine
- Dermatology
- Endocrinology
- Oral Medicine
- Otorhinolaryngologic Diseases
- Pain
- Gastrointestinal Disorders
- Geriatrics
- Infection
- Musculoskeletal Disorders
- Obesity
- Rheumatology
- Technology
- Cancer
- Nephrology
- Anemia
- Neurology
- Pulmonology
Adverse Events Observed in Study of Nirsevimab for RSV
Experts discuss the results of the safety and efficacy study of nirsevimab for Respiratory Syncytial Virus (RSV) commenting on the adverse events observed in the test and placebo groups.
EP: 1.Introduction and Overview of RSV and Nirsevimab
EP: 2.Prevalence and Clinical Gaps of RSV
EP: 3.Study Background on Single-Dose Nirsevimab for RSV
EP: 4.Discussion of Study Patient Population on Nirsevimab for RSV
EP: 5.Data Review of Efficacy and Safety Study of Nirsevimab for RSV
EP: 6.Time-To-Event Analysis and Discussion on the Efficacy Nirsevimab for RSV
EP: 7.RSV Strains and Nirsevimab for RSV
EP: 8.Infant Weight and Efficacy Outcomes of Nirsevimab for RSV
EP: 9.Adverse Events Observed in Study of Nirsevimab for RSV
EP: 10.Dosing Strategy and Final Pearls for Nirsevimab for RSV
Transcript
Tina Tan, MD, FAAP, FIDSA, FPIDS: The other thing that’s really important when you look at the study is if you look at the adverse events [AEs] that occurred with this monoclonal, there was not much of a difference between the group that got the monoclonal vs the placebo group. And if you look at those who had serious [AEs]…the investigators all felt that the serious [AEs] were not related to the infant either receiving their nirsevimab or the placebo. So, it appears that this monoclonal antibody is actually quite safe to administer to infants of all the different ages to protect them against [respiratory syncytial virus].
Flor M. Munoz, MD, MSc: Right. The [AE] profile is quite balanced. This is exactly why we need placebo groups in these studies. And again, the distribution of the groups by age and by geographic location was quite balanced. I think the [AEs], which could be recorded after administration of this monoclonal antibody, where you have very similar results very much apart between the vaccine and placebo means that other things happen—babies can have fevers or…another set of symptoms—that, in this case, do not seem to be seen more frequently in the group that received the product. So, I agree. Overall, even though this is an injection, there was no obvious direct association with any of these events, including the serious [AEs] to being in the study or receiving the product.
Transcript is AI-generated and edited for clarity.
